A detailed history of Deutsche Bank Ag\ transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 30,942 shares of TBPH stock, worth $305,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,942
Previous 22,061 40.26%
Holding current value
$305,088
Previous $187,000 33.16%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.66 - $10.25 $68,028 - $91,030
8,881 Added 40.26%
30,942 $249,000
Q2 2024

Aug 14, 2024

SELL
$8.29 - $9.92 $47,841 - $57,248
-5,771 Reduced 20.74%
22,061 $187,000
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $3,559 - $5,018
433 Added 1.58%
27,832 $249,000
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $6,314 - $8,390
-736 Reduced 2.62%
27,399 $307,000
Q3 2023

Nov 09, 2023

BUY
$8.38 - $10.44 $34,676 - $43,200
4,138 Added 17.24%
28,135 $242,000
Q2 2023

Aug 14, 2023

SELL
$10.16 - $11.92 $242,732 - $284,780
-23,891 Reduced 49.89%
23,997 $248,000
Q1 2023

May 15, 2023

BUY
$9.87 - $11.44 $58,519 - $67,827
5,929 Added 14.13%
47,888 $519,000
Q4 2022

Feb 13, 2023

BUY
$9.65 - $11.34 $114,796 - $134,900
11,896 Added 39.57%
41,959 $470,000
Q3 2022

Nov 14, 2022

SELL
$8.39 - $10.22 $88,187 - $107,422
-10,511 Reduced 25.91%
30,063 $305,000
Q2 2022

Aug 11, 2022

SELL
$8.41 - $10.34 $15,070 - $18,529
-1,792 Reduced 4.23%
40,574 $368,000
Q1 2022

May 13, 2022

SELL
$8.33 - $12.96 $29,179 - $45,398
-3,503 Reduced 7.64%
42,366 $406,000
Q4 2021

Feb 11, 2022

BUY
$7.42 - $11.05 $42,798 - $63,736
5,768 Added 14.38%
45,869 $507,000
Q3 2021

Nov 04, 2021

BUY
$6.77 - $14.41 $19,382 - $41,255
2,863 Added 7.69%
40,101 $297,000
Q2 2021

Aug 11, 2021

SELL
$14.52 - $22.46 $2.43 Million - $3.75 Million
-167,048 Reduced 81.77%
37,238 $541,000
Q1 2021

May 13, 2021

SELL
$16.57 - $21.08 $177,050 - $225,239
-10,685 Reduced 4.97%
204,286 $4.17 Million
Q4 2020

Feb 16, 2021

SELL
$14.89 - $20.16 $696,420 - $942,903
-46,771 Reduced 17.87%
214,971 $3.82 Million
Q3 2020

Nov 12, 2020

SELL
$14.79 - $22.49 $3.26 Million - $4.95 Million
-220,279 Reduced 45.7%
261,742 $3.87 Million
Q2 2020

Aug 13, 2020

BUY
$20.64 - $30.69 $116,306 - $172,938
5,635 Added 1.18%
482,021 $10.1 Million
Q1 2020

May 14, 2020

BUY
$17.84 - $31.21 $7.76 Million - $13.6 Million
434,938 Added 1049.36%
476,386 $11 Million
Q4 2019

Feb 14, 2020

BUY
$16.12 - $25.89 $459,726 - $738,356
28,519 Added 220.58%
41,448 $1.07 Million
Q3 2019

Nov 14, 2019

SELL
$16.51 - $23.78 $239,626 - $345,142
-14,514 Reduced 52.89%
12,929 $250,000
Q2 2019

Aug 14, 2019

SELL
$15.6 - $25.15 $451,635 - $728,117
-28,951 Reduced 51.34%
27,443 $446,000
Q1 2019

May 15, 2019

BUY
$22.57 - $28.15 $90,280 - $112,600
4,000 Added 7.63%
56,394 $1.28 Million
Q4 2018

Feb 14, 2019

SELL
$22.52 - $35.07 $3.16 Million - $4.93 Million
-140,498 Reduced 72.84%
52,394 $1.34 Million
Q3 2018

Dec 21, 2021

BUY
$22.83 - $32.67 $538,354 - $770,391
23,581 Added 13.93%
192,892 $6.3 Million
Q3 2018

Nov 14, 2018

BUY
$22.83 - $32.67 $1.09 Million - $1.57 Million
47,941 Added 39.5%
169,311 $5.53 Million
Q2 2018

Apr 21, 2020

BUY
$22.06 - $25.52 $507,225 - $586,781
22,993 Added 23.37%
121,370 $2.75 Million
Q2 2018

Aug 14, 2018

SELL
$22.06 - $25.52 $240,851 - $278,627
-10,918 Reduced 9.99%
98,377 $2.23 Million
Q1 2018

Oct 18, 2019

BUY
$23.37 - $29.71 $575,696 - $731,876
24,634 Added 29.1%
109,295 $2.65 Million
Q1 2018

May 15, 2018

SELL
$23.37 - $29.71 $562,959 - $715,684
-24,089 Reduced 22.15%
84,661 $2.05 Million
Q4 2017

Feb 14, 2018

BUY
$25.82 - $35.66 $1.27 Million - $1.75 Million
49,137 Added 82.43%
108,750 $3.03 Million
Q3 2017

Nov 14, 2017

BUY
$23.88 - $34.96 $1.42 Million - $2.08 Million
59,613
59,613 $2.04 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $658M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Deutsche Bank Ag\ Portfolio

Follow Deutsche Bank Ag\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.